Global Health

Our approach to social impact starts with our medicines and our commitment to expand access to those medicines to as many people as possible. We extend our reach by being part of the solution for complex global health challenges that disproportionately affect people living in settings with limited resources.

We expand our impact even further by working to strengthen communities around the world. We invest our resources, time and expertise to drive social impact, with a focus on improving health and education. We encourage and support our employees’ efforts to give and volunteer in ways that help make life better.

COVID-19 Response

The global pandemic brought on by COVID-19 has changed the world as we know it. At Lilly, we joined our industry partners in bringing the unique scientific and medical expertise of the pharmaceutical industry to bear in the crisis. Find out how we continue to work together with partners around the world to help affected patients and communities.

Reaching Children with Diabetes

Since 2009, Lilly has donated more than 3.2 million vials and cartridges of insulin through our partnership with Life for a Child.

Improving Screening for Breast and Cervical Cancer in Kenya

As of 2021, 126,000 people have been screened for breast and cervical cancer in Kenya through our AMPATH partnership. Community health screening has enabled people like Nancy Odari to receive early diagnosis and treatment.

Improving the Health of Communities

More than 1,500 Lilly employees have volunteered through our Connecting Hearts Abroad programme focused on improving the health of communities with limited resources in Asia, Africa and Central and Southern America.

Lilly 30x30

Globally, we’ve established an aggressive goal – Lilly 30x30 – to improve access to quality health care for 30 million people, each year, by 2030. We focus on people living in communities with limited resources, including those who might not be reached by Lilly’s traditional business model.

Reaching our 30x30 goal will take far more than philanthropy. It requires a stronger mix of creative approaches across our business and with our partners that help expand access for more people.

We focus our 30x30 effort in three key areas:

• Pipeline: Discovering medicines and repurposing internal assets and legacy products for diseases that disproportionately affect people in resource-limited settings.

• Programs: Strengthening and creating new programs that help improve access to Lilly medicines.

• Partnerships: Building partnerships that strengthen health systems, increase access to medicines and improve care.